Medicine consulting firm DeciBio Consulting reported on Thursday the availability of the Emmes SARS-CoV-2 Testing Database that includes diagnostic and serology testing details at hospital, public health, commercial reference labs, as well as send-out volumes.

According to the company, the DeciBio Emmes SARS-CoV-2 Testing Database reportedly provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the US. The database and easy-to-navigate visualization suite are available on a subscription basis for clients in sales, development, strategic, investment analytics / market research and operations roles.

This database is latest addition to the market intelligence products including the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter and BioTrack under DeciBio Consulting's umbrella. The database collects information on platforms and kits used, sample collection devices, co-testing behaviors and more.

The company said the preliminary results indicate nearly half of labs have reported that kit availability fails to meet demand, one third of surveyed labs use multiple platforms testing at these labs and account for total volumes for the database, some labs have reported reduced operational hours affecting testing outputs and the serology test adoption is beginning to mature but lags behind diagnostic testing.